NCT03772613View on ClinicalTrials.gov

The Randomized OPTIMAL-ACT Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

February 8, 2019

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
Coronary Artery DiseaseIschemic Heart DiseaseAnticoagulant-induced BleedingCoronary Syndrome
Interventions
DRUG

Unfractionated heparin

Administration of unfractionated heparin will be assessed using the activated clotting time

Trial Locations (1)

32224

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER